API-CAT establishes reduced-dose apixaban "as an appropriate regimen ... lower rates of clinically relevant bleeding in the half-dose DOAC arm than the full-dose DOAC arm." He predicted an ...

CHICAGO — Extended therapy with reduced-dose apixaban is just as effective as the high dose in preventing recurrent venous thromboembolism (VTE) in patients with active cancer who completed at ...

The aim of the API-CAT trial was to assess whether the lower dose of apixaban was comparable to the full dose in preventing VTE recurrence in patients with active cancer who had completed at least ...

In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant ... a 1:1 ratio to receive oral apixaban at a reduced (2.5 ...

The Phase III API-CAT trial found that extended anticoagulant therapy with reduced-dose Eliquis (apixaban) was noninferior to the full-dose regimen in preventing recurrent venous thromboembolism in ...

Isabelle Mahé, M.D., Ph.D., a professor of internal medicine at the Université Paris Cité and head of internal medicine at Public Assistance Hospitals of Paris, and her colleagues reported results ...

Extended anticoagulant therapy with a reduced-dose of apixaban was noninferior to extended therapy with a full-dose of apixaban in preventing recurrent venous thromboembolism (VTE) in patients with ...

A NEW study has shown that extended treatment with a reduced dose of apixaban can effectively prevent recurrent venous thromboembolism (VTE) in cancer patients while reducing the risk of bleeding.

CHICAGO, IL—For patients with active cancer who’ve had venous thromboembolism (VTE), 12-month extended anticoagulation with reduced-dose apixaban is noninferior to the full dose at preventing ...